Jiangsu Vcare Closes Series A2 Financing
Published Time:
2022-05-06 17:26
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series A2 financing round. This marks the successful closing of the company’s Series A financing, bringing the total Series A funding to nearly $60 million. This round was led by existing investor SDIC Capital, with co-investment from Yangtze River Industry Group. The proceeds will primarily support the R&D of innovative drug candidates as well as the construction of R&D and production bases for its CDMO business.
Currently, Jiangsu Vcare’s innovative drug pipeline is advancing steadily, with multiple drug candidates progressing through key stages. In 2022, several programs reached critical milestones:Vicagrel, a new cardiovascular and cerebrovascular drug (targeting P2Y12), obtained clinical approval from the US FDA. The drug has already initiated Phase III clinical research in China, with a research protocol that meets the requirements for both Chinese and US filings, and the US clinical trial is about to start; VC004, an anti-tumor new drug (targeting NTRK), has enrolled multiple patients in its Ib trial with significant efficacy, and the US IND application is soon to be submitted; VC005, a highly selective JAK1 inhibitor, is about to complete the SAD study, showing favorable preliminary safety and PK-PD properties. Additionally, nearly ten innovative drug candidates are in active development. The company’s wholly-owned subsidiary, Nanjing Vcare Pharmatech Co., Ltd. , continues to enhance its integrated CRO/CDMO services. Its Phase II CDMO R&D Technology Center is nearing completion, and the acquisition and construction of CDMO manufacturing facilities are progressing rapidly. With investor support, Jiangsu Vcare will accelerate its dual-track strategy: advancing proprietary drug development while expanding comprehensive drug industry chain services.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "We are honored by the continued trust of our existing shareholders and deeply grateful for the recognition from new investors. Together, we will integrate resources to empower Vcare’s growth, accelerating the development of our integrated CRO/CDMO platform. We are proud to contribute our team’s decades of industry expertise, innovative technologies, internationally compliant manufacturing controls, and commitment to green chemistry principles to China’s dynamic and innovative pharmaceutical sector. This collaboration will strengthen China’s pharmaceutical supply chain, accelerate global integration, and deliver sustainable long-term value for our shareholders."
Related News
12
2026
/
11
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) has officially launched a clinical trial for the new indication of bone metastatic cancer pain of Eratrectinib Capsules (VELMARTO®, VC004), a Class 1 innovative drug independently developed by the company. This move further expands the clinical application scope of this next-generation TRK inhibitor and explores an innovative treatment option for patients suffering from bone metastatic cancer pain.
28
2026
/
10
Recently, VC005 topical gel,balanced, highly selective new-generation JAK1 inhibitor, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), has officially received the IND clearance from the NMPA. It is intended for the topical treatment of seborrheic dermatitis.
20
2026
/
10
Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) recently announced that its self-developed VC005 topical gel, balanced, highly selective new-generation JAK1 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD) in adults and adolescents, has successfully completed full participant enrollment in its Phase III clinical trial. This milestone marks steady progress for the topical product toward the NDA.
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.